Biocept Inc. (BIOC)

0.24
NASDAQ : Health Technology
Prev Close 0.24
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.23 / 1.90
Avg Volume 2.74M
Exchange NASDAQ
Shares Outstanding 68.04M
Market Cap 16.57M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biocept Obtains Patent For Its Target Selector Molecular Biomarker Technology In China

Biocept Obtains Patent For Its Target Selector Molecular Biomarker Technology In China

Expands intellectual property position to 26 issued patents globally for Biocept's highly sensitive methods for detecting cancer biomarkers found in tissue, blood and other biological sources

Biocept And Thermo Fisher Scientific Enter Into Technology And Commercial Collaboration

Biocept And Thermo Fisher Scientific Enter Into Technology And Commercial Collaboration

Collaboration plans to establish Biocept as Thermo Fisher Center of Excellence for liquid biopsy and to pursue commercial opportunities in both pharmaceutical and clinical markets

Biocept's Target Selector Platform Featured In Two Poster Presentations At The 2018 American Association For Cancer Research Annual Meeting

Biocept's Target Selector Platform Featured In Two Poster Presentations At The 2018 American Association For Cancer Research Annual Meeting

Data highlights clinical proof-of-concept for monitoring metastatic testicular cancer using the Company's proprietary CTC assays, as well as validation of Biocept's high sensitivity circulating tumor DNA tests on Thermo Fisher QuantStudio™5 instrument

Biocept Receives Additional Patent Issuances In Three Major International Territories For Its Target Selector Platform

Biocept Receives Additional Patent Issuances In Three Major International Territories For Its Target Selector Platform

Intellectual property estate now includes 25 issued patents for Biocept's highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs)

Biocept Comments On Updated Consensus Medical Guidelines Recommending Liquid Biopsy For Profiling Of Tumor Biomarkers To Assist With The Treatment Of Patients With Lung Cancer

Biocept Comments On Updated Consensus Medical Guidelines Recommending Liquid Biopsy For Profiling Of Tumor Biomarkers To Assist With The Treatment Of Patients With Lung Cancer

Published medical guidelines influence treatment practices and can drive clinical adoption of emerging technologies designed to improve the treatment of serious or life-threatening diseases

Biocept Obtains Patent In Australia For Its Molecular Biomarker Technology For The Detection Of Cancer-Associated Mutations In Blood, Tissue, And Other Biological Sources

Biocept Obtains Patent In Australia For Its Molecular Biomarker Technology For The Detection Of Cancer-Associated Mutations In Blood, Tissue, And Other Biological Sources

Expands intellectual property position to 22 issued patents globally for Biocept's highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs)

First U.S. Patent Issued For Biocept's Target Selector Oncogene Mutation Enrichment And Detection Liquid Biopsy CtDNA Platform

First U.S. Patent Issued For Biocept's Target Selector Oncogene Mutation Enrichment And Detection Liquid Biopsy CtDNA Platform

Expands Biocept's intellectual property portfolio to 21 issued patents for its highly sensitive methods of detecting cancer biomarkers on circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA)

Biocept And UC San Diego Medical Center Announce Clinical Study Collaboration To Demonstrate Utility Of Biocept's Liquid Biopsy Test In Immunotherapy

Biocept And UC San Diego Medical Center Announce Clinical Study Collaboration To Demonstrate Utility Of Biocept's Liquid Biopsy Test In Immunotherapy

Clinical validation of Biocept's novel PD-L1 test using multiple antibody clones has potential to improve detection, treatment selection, and patient monitoring with cancer immunotherapy

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Stocks with insider trader activity include BA, WLL and BIOC

8 Stocks Under $10 to Trade for Big Gains

8 Stocks Under $10 to Trade for Big Gains

These under-$10 stocks are making big moves higher. Here's how to trade them from here.

Biocept (BIOC) Stock Popping on Blue Cross Blue Shield Partnership

Biocept (BIOC) Stock Popping on Blue Cross Blue Shield Partnership

Biocept (BIOC) stock is surging in mid-morning trading on Tuesday after the company announced an agreement with Blue Cross Blue Shield of Illinois.

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc.

Lung Cancer Study Demonstrates Extremely High Sensitivity Of Biocept's Blood-Based Liquid Biopsy Platform In Detecting EGFR Mutation In Plasma With 93% Concordance With Tissue Biopsy

Lung Cancer Study Demonstrates Extremely High Sensitivity Of Biocept's Blood-Based Liquid Biopsy Platform In Detecting EGFR Mutation In Plasma With 93% Concordance With Tissue Biopsy

Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, today announced that findings...

Biocept To Present At 2015 Aegis Growth Conference

Biocept To Present At 2015 Aegis Growth Conference

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael Nall is scheduled to...

Biocept Announces Participation In MultiPlan's Networks

Biocept Announces Participation In MultiPlan's Networks

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that it has entered into an agreement with MultiPlan,...

Biocept Secures Agreements With Preferred Provider Organizations Stratose And Galaxy Health Network For Its Proprietary Blood-Based Oncology Diagnostic Assays

Biocept Secures Agreements With Preferred Provider Organizations Stratose And Galaxy Health Network For Its Proprietary Blood-Based Oncology Diagnostic Assays

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing assays for liquid biopsies to improve the detection and treatment of cancer, announces additional agreements with preferred...

Biocept Expands U.S. Microchannel Patent Protection

Biocept Expands U.S. Microchannel Patent Protection

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces the allowance of U.

Biocept's Liquid Biopsy Lung Cancer Target Selector Assay To Be Featured At World Conference On Lung Cancer

Biocept's Liquid Biopsy Lung Cancer Target Selector Assay To Be Featured At World Conference On Lung Cancer

Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that clinical data from a study conducted with...

TheStreet Quant Rating: E+ (Sell)